Next generation antibody-drug conjugates
Developing best in class oncology treatments
At NBE Therapeutics we strive to develop best-in-class oncology treatments to increase survival and improve quality of life for cancer patients worldwide. Through our highly innovative novel in-house developed technologies, we have created a next generation antibody-drug conjugate platform targeting solid tumors.
Our platform allows us to develop targeted medicines, that through a long-lasting immune oncology effect, could reduce or even eradicate tumors. Our dedicated international team has been able to create a pipeline of ADC product candidates in various stages of development to enter clinical phases to create better treatments for cancer patients in need of more selective drugs.